Register entry
Boehringer Ingelheim Espaa, S.A.
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 2 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 2.
| Dosage form | NDCs |
|---|---|
| tablet | 2 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| boehringer ingelheim espaa, s.a. | 2 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | empagliflozin | tablet | 83248-030DRUG FOR FURTHER PROCESSING |
| - | empagliflozin | tablet | 83248-040DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing empagliflozin
- Macleods Pharmaceuticals Limited5 sites · 390 NDC
- Boehringer Ingelheim Promeco S.A. de C.V.1 site · 3 NDC
- BOEHRINGER INGELHEIM HELLAS SINGLE MEMBER S.A.1 site · 2 NDC
Enquiry
Common questions
- Is Boehringer Ingelheim Espaa, S.A. FDA approved?
- Boehringer Ingelheim Espaa, S.A. holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Boehringer Ingelheim Espaa, S.A. make?
- 2 products are listed under Boehringer Ingelheim Espaa, S.A. in the openFDA NDC Directory, most often as tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.